Adanma Anji Ayanambakkam Attanathi
Hematology & Oncology · Oklahoma City, OKNPI 1265813513
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson at 38.8% of the total. 2025 is the largest year on record at $6,495, 5.6 times the $1,161 reported in 2019.
Across 132 payments — averaging $118.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$6K
- Pfizer$6K
- AVEO Pharmaceuticals, Inc.$2K
- Bristol Myers Squibb$258
- Astellas Pharma US Inc$191
- AstraZeneca$168
- plus $1K from 16 others
Across 57 payments — averaging $33,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
- Seagen Inc.$66K
- Janssen Research & Development, LLC$5K
- Exelixis Inc.$600
What the payments were for
- Consulting fees$6,99145%
- Speaking & faculty fees$4,42428%
- Travel & lodging$1,58810%
- Food & beverage$2,34315%
- Education$2502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $6,049 |
| Pfizer | 26 | $5,835 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,815 |
| Bristol Myers Squibb | 19 | $258 |
| Astellas Pharma US Inc | 8 | $191 |
| AstraZeneca | 8 | $168 |
| Merck | 7 | $162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $153 |
| Bayer | 11 | $144 |
| Caris MPI, Inc. | 1 | $133 |
| Novartis | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $108 |
| Lilly USA, LLC | 7 | $102 |
| Incyte Corporation | 5 | $80 |
| Agios Pharmaceuticals, Inc. | 4 | $60 |
| Rigel Pharmaceuticals, Inc. | 3 | $56 |
| Amgen | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Gilead | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$5,987
- PADCEV$5,200
- AKEEGA$4,725
- FOTIVDA$1,815
- MI CANCER SEEK$133
How this compares
$15,596 in reported general payments places this provider in the 85th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 100 | $2,488,969 |
| InlytaAxitinib | 105 | $1,912,587 |
| XtandiEnzalutamide | 146 | $1,909,981 |
| NubeqaDarolutamide | 123 | $1,549,653 |
| FotivdaTivozanib Hcl | 31 | $907,244 |
| LynparzaOlaparib | 23 | $336,709 |
| Abiraterone Acetate | 239 | $191,837 |
| TagrissoOsimertinib Mesylate | 12 | $189,816 |
| TalzennaTalazoparib Tosylate | 12 | $155,576 |
| OrgovyxRelugolix | 19 | $51,053 |
| EliquisApixaban | 44 | $31,973 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 87 | $1,650 |
| Prednisone | 301 | $1,556 |
| Morphine Sulfate ErMorphine Sulfate | 69 | $1,411 |
| Ondansetron OdtOndansetron | 51 | $1,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Talzenna, Eliquis | $5,835 | $2,100,136161 claims |
| Astellas Pharma US IncXtandi | $191 | $1,909,981146 claims |
| BayerNubeqa | $144 | $1,549,653123 claims |
| AstraZenecaLynparza, Tagrisso | $168 | $526,52535 claims |
| Lilly USA, LLCOlanzapine | $102 | $17917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
- Charles HollenOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.